Interestingly, there was also an induction of CDKN1A expression in OCI-AML2 and MV4-11 cells treated with 50 nM cobimetinib, but not in MOLM13 cells, indicating that MEK inhibition can lead to p53 activation, at least in some AML cells. Here, MAP2K7 is linked to acute myeloid leukemia.